References: UDENYCA Prescribing Information. Coherus BioSciences; December 2023. All trademarks, logos and brand names are the property of their respective owners.

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company; NASDAQ: CHRS) today announced the completion of the previously announced divestiture of ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS) today announced the completion of the previously announced divestiture of its UDENYCA (pegfilgrastim-cbqv ...

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Monday announced the completion of its previously announced divestiture of the UDENYCA or pegfilgrastim-cbqv franchise to Intas Pharmaceuticals Ltd ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company; NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its ...

Coherus, meanwhile, said the sale of its Udencya franchise reduces its debt and will help it focus on novel cancer programs. Its cancer portfolio includes Loqtorzi — the only Food and Drug ...